GlassScriptPhysician profile
Shmuel Neiman
NPI 1336361344
$2,525.74
in general payments reported to CMS, 2019-2025
17 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $531 · 2023: $207 · 2024: $866 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $506.73 | 2022-2024 | Kcentra |
| Aop Health US, LLC | $335.38 | 2025 | Rapiblyk |
| Genzyme Corporation | $298.63 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $273.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $172.44 | 2021-2023 | Farxiga |
| Pfizer INC. | $161.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $124.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $124.83 | 2022 | |
| Blueprint Medicines Corporation | $109.37 | 2024 | |
| Abbvie INC. | $101.79 | 2025 | |
| Alnylam Pharmaceuticals INC. | $58.51 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $38.05 | 2023 | Xarelto |
| Amgen INC. | $30.05 | 2024 | |
| Paratek Pharmaceuticals, INC. | $25.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.48 | 2024 | Eliquis |
| Scpharmaceuticals INC. | $15.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shmuel Neiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.